1. Home
  2. ARL vs LYEL Comparison

ARL vs LYEL Comparison

Compare ARL & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Realty Investors Inc.

ARL

American Realty Investors Inc.

N/A

Current Price

$16.07

Market Cap

259.7M

Sector

Real Estate

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$10.96

Market Cap

320.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARL
LYEL
Founded
1999
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.7M
320.1M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
ARL
LYEL
Price
$16.07
$10.96
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
1.9K
98.2K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
206.59
N/A
EPS
N/A
N/A
Revenue
$50,014,000.00
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
5.70
N/A
52 Week Low
$12.42
$11.47
52 Week High
$24.44
$45.00

Technical Indicators

Market Signals
Indicator
ARL
LYEL
Relative Strength Index (RSI) 54.90 28.91
Support Level $15.65 N/A
Resistance Level $16.83 $15.38
Average True Range (ATR) 0.39 0.84
MACD 0.12 -0.44
Stochastic Oscillator 55.61 7.41

Price Performance

Historical Comparison
ARL
LYEL

About ARL American Realty Investors Inc.

American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: